Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours

I.R.H.M. Konings, M.J.A. de Jonge, H. Burger, A. van der Gaast, L.E.C. van Beijsterveldt, H. Winkler, J. Verweij, Z. Yuan, P. Hellemans, F.A.L.M. Eskens

Research output: Contribution to journalArticleAcademicpeer-review

63 Downloads (Pure)
Original languageUndefined/Unknown
Pages (from-to)987-992
JournalBritish Journal of Cancer
Volume103
Issue number7
DOIs
Publication statusPublished - 2010

Cite this

Konings, I. R. H. M., de Jonge, M. J. A., Burger, H., van der Gaast, A., van Beijsterveldt, L. E. C., Winkler, H., ... Eskens, F. A. L. M. (2010). Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours. British Journal of Cancer, 103(7), 987-992. https://doi.org/10.1038/sj.bjc.6605867